Akebia Reports 49% Revenue Jump to $227M, 290,000 Patients on Vafseo
Akebia’s Q4 net product revenues reached $54.3 million, driving full-year 2025 net product revenues to $227.3 million, a 49% increase over 2024. Patient access to Vafseo now covers 290,000 individuals, with prescribers up 10% in Q4 and refill adherence rising to 91%.
1. Financial Performance
Akebia reported fourth-quarter 2025 net product revenues of $54.3 million and total revenues of $57.6 million, compared with $46.5 million in Q4 2024. Full-year net product revenues rose 49% to $227.3 million, while total 2025 revenues climbed to $236.2 million from $160.2 million in 2024.
2. Vafseo Commercial Momentum
Patient access to Vafseo expanded to 290,000 individuals by year-end, supported by approximately 800 prescribers, a 10% increase over Q3. Q4 patient demand was $11 million, and adoption of in-center observed dosing drove refill adherence up to 91% from 75% earlier in 2025.
3. Pipeline Progress
Enrollment is underway in a Phase 2 praliciguat trial in focal segmental glomerulosclerosis targeting 60 patients, and a Phase 2 AKB-097 rare kidney disease basket study is set to begin in the second half of 2026. Meanwhile, the Phase IIIb VOCAL trial will report topline data in Q4 2026, the Phase IV VOICE trial results in early 2027, and a Phase 1 AKB-9090 study will start in H1 2026.